跳至主要内容
临床试验/JPRN-UMIN000045792
JPRN-UMIN000045792已完成未知

Clinical validity of mutated DNA monitoring in plasma and urinary pellet in recurrent diagnosis of bladder cancer - Mutated DNA monitoring in plasma and urinary pellet in recurrent diagnosis of bladder cancer

Iwate Medical University Institute for Biomedical Sciences Division of Biomedical Research and Development0 个研究点目标入组 33 人开始时间: 2021年11月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
33

研究概览

简要总结

Most (30/32; 93.8%) cases showed at least one traceable somatic mutation. In 5 of 7 (71.4%) cases with clinical recurrence, upDNA VAF >1% was detected 7-15 months earlier than the imaging diagnosis. The upDNA VAF remained high after initial treatment for locally recurrent cases. The clinical validity of upDNA monitoring was confirmed with the observation that 26 of 30 (86.7%) cases were traceable.

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Patients who have difficulty in outpatient visits 2)Patients with psychiatric symptoms who have difficulty participating in the study 3)Patients with serious complications 4)Patients judged by the principal investigator to be inappropriate for registration 5)Cases in which pathological diagnosis and sequence analysis cannot be compatible due to the small amount of tumor sample

研究者

发起方
Iwate Medical University Institute for Biomedical Sciences Division of Biomedical Research and Development

相似试验